Cytosorbents Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corporation on February 28, 2018. The report discloses the approval of equity bonus awards for executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements.
Material Changes
The primary material event is the grant of Restricted Stock Units (RSUs) to four executive officers in recognition of the Company's 2017 performance. The awards were granted under the 2014 Long-Term Incentive Plan with a 10-year term.
- Phillip P. Chan, MD, PhD (President and CEO): 43,000 RSUs
- Vincent J. Capponi (COO): 38,000 RSUs
- Kathleen P. Bloch (CFO): 34,700 RSUs
- Eric R. Mortensen (CMO): 14,000 RSUs
Vesting occurs in three equal tranches: one-third on the date of grant, one-third on the first anniversary, and one-third on the second anniversary, subject to continued service.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risks, contingencies, or unusual items beyond the standard vesting conditions of the equity awards.
Key Facts for Investor Verification
- Verify the total number of RSUs granted (129,700) and the specific vesting schedule (33% annually over three years).
- Confirm the impact of these awards on the company's share count and potential dilution upon settlement.
- Review the 2014 Long-Term Incentive Plan to understand the full terms and conditions of the grants.
- Note that the awards are tied to 2017 performance, though specific performance metrics are not detailed in this filing.